School of Veterinary Medicine, University of Glasgow, Glasgow, UK.
J Vet Intern Med. 2011 Mar-Apr;25(2):251-60. doi: 10.1111/j.1939-1676.2011.0696.x. Epub 2011 Feb 25.
Trilostane is a recognized treatment for canine pituitary-dependent hyperadrenocorticism (PDH); however, its efficacy in dogs with adrenal-dependent hyperadrenocorticism (ADH) is unknown.
To examine factors that might influence survival in the medical management of ADH, with particular emphasis on treatment selection.
Thirty-seven animals referred to 4 centers over a period of 12 years that had been diagnosed with ADH and treated with either trilostane (22/37), mitotane (13/37), or both (2/37).
Retrospective analysis of clinical records.
There was no statistically significant difference between the survival times of 13 dogs treated only with mitotane when compared with 22 dogs treated only with trilostane. The median survival time for animals treated with trilostane was 353 days (95% confidence interval [CI] 95-528 days), whereas it was 102 days (95% CI 43-277 days) for mitotane. Metastatic disease was detected in 8 of 37 dogs. There was a significantly lower probability of survival for dogs with metastatic disease when compared with those without metastatic disease (P < .001).
The choice of medical treatment for ADH may not have a major effect on survival times. However, the presence of metastatic disease considerably decreases survival time regardless of the choice of medical treatment.
曲洛司坦是一种被认可的治疗犬垂体依赖性库欣病（PDH）的方法；然而，其在肾上腺依赖性库欣病（ADH）犬中的疗效尚不清楚。
研究可能影响 ADH 内科治疗生存的因素，特别强调治疗选择。
在 12 年期间，有 37 只动物被转诊至 4 个中心，被诊断为 ADH，并分别接受曲洛司坦（22/37）、米托坦（13/37）或两者（2/37）治疗。
回顾性临床病历分析。
仅接受米托坦治疗的 13 只狗与仅接受曲洛司坦治疗的 22 只狗的生存时间无统计学显著差异。接受曲洛司坦治疗的动物的中位生存时间为 353 天（95%置信区间[CI]95-528 天），而接受米托坦治疗的动物的中位生存时间为 102 天（95%CI43-277 天）。37 只狗中有 8 只检测到转移性疾病。与无转移性疾病的狗相比，患有转移性疾病的狗的生存概率显著降低（P<0.001）。
ADH 的内科治疗选择可能不会对生存时间产生重大影响。然而，无论选择何种内科治疗，转移性疾病的存在都会显著降低生存时间。
